UroGen Pharma Ltd. (URGN) · Nov 4, 2026 · Earnings
Guidance cut — FY JELMYTO revenue ~$90M vs. prior $97M-$101M
UroGen’s earnings show meaningful pipeline progress, but a JELMYTO guidance cut exposes near-term commercial pressure and slower patient starts.
UroGen is transitioning from a JELMYTO-led commercial business toward scaling ZUSDURI while building a broader bladder-cancer pipeline around UGN-103 and UGN-501. Earlier 2026 expectations already included strong ZUSDURI growth, an UGN-103 NDA submission, and a late-2026 UGN-501 trial start, so much of the pipeline progress here confirms the existing plan rather than rewriting it.
| Metric | Q3 2026 | Q3 2025 | Consensus / prior guidance |
|---|---|---|---|
| Net product revenue (Financial Highlights) | $21.0M (-18.3%) | $25.7M | |
| Net loss per share (Net Loss) | $(0.03) | $(0.69) | ~$0.10 EPS* |
| FY JELMYTO revenue (Guidance) | ~$90M | $97M-$101M | |
| R&D expense (R&D Expenses) | $26.0M | $14.0M | |
| SG&A expense (SG&A Expenses) | $47.2M | $37.6M |
*The published consensus was roughly $0.10-$0.11 per share, but its basis is not identified here, so the reported GAAP loss is not a clean apples-to-apples earnings comparison.
The important negative is the commercial reset. UroGen cut full-year JELMYTO revenue guidance to approximately $90 million from $97 million-$101 million, attributing the shortfall to a $1.5 million CMS true-up and competitive clinical-trial enrollment reducing patient starts. That is more than a one-time accounting issue: the filing also identifies ongoing competition for patients, suggesting the legacy product is facing execution and demand pressure.
The pipeline is advancing, but mostly along an already-known path. The FDA accepted UGN-103 for review and set a June 14, 2027 PDUFA date, while UroGen plans a high-risk NMIBC Phase 3 study and has begun dosing UGN-501. 〔0〕 These are real de-risking steps, but NDA acceptance and the UGN-501 start were already disclosed before this quarterly release; the new information is mainly the formal review timeline, patent duration, and continued execution.
The quarter itself improved financially, but not enough to offset the guidance cut. The reported loss narrowed sharply from $33.3 million to $1.5 million, yet R&D and commercial spending rose as UroGen funds UGN-103, UGN-501, and ZUSDURI adoption.
Bottom line: UroGen is making credible pipeline progress, but the immediate commercial story weakened because JELMYTO guidance was cut and patient starts remain under pressure. The event is mixed, leaning negative, rather than a clean step forward for the business story.
FDA decision on UGN-103, June 14, 2027
A buy-side analyst on every ticker — it reads every public company's filing the instant it drops and decodes it into plain English.
A buy-side analyst on every ticker — the whole market decoded the second it moves, before it's a headline. Free gives you a taste. Pro takes the cap off and opens the full read on every company.
by Signing in NOW, claim your FREE 14-day Pro trial!